Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence
- PMID: 3550149
- DOI: 10.1016/s0022-5347(17)44172-3
Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence
Abstract
To evaluate the efficacy and safety of intracavernous self-injection of phentolamine and papaverine for the treatment of impotence, 30 patients were enrolled in a prospective, randomized, double-blind, placebo-controlled cross-over study of papaverine and phentolamine versus normal saline. A total of 29 patients completed the study. The phentolamine plus papaverine combination resulted in erection in 24 patients (82.8 per cent) and no erection occurred after injection of saline. Of the patients 12 (41.4 per cent) experienced technical difficulties with the injection. Ecchymosis of the penis at the site of injection was common and 1 patient experienced priapism that resolved spontaneously. No other side effects occurred. Intracavernous self-injection with phentolamine and papaverine appears to be a safe and effective treatment of impotence but long-term effects must be determined.
Similar articles
-
Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.J Urol. 1989 Mar;141(3):549-50. doi: 10.1016/s0022-5347(17)40889-5. J Urol. 1989. PMID: 2918589 Clinical Trial.
-
Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial.J Urol. 1989 Sep;142(3):726-8. doi: 10.1016/s0022-5347(17)38868-7. J Urol. 1989. PMID: 2671414 Clinical Trial.
-
Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.Paraplegia. 1986 Oct;24(5):271-5. doi: 10.1038/sc.1986.37. Paraplegia. 1986. PMID: 3774363
-
[Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].Actas Urol Esp. 1992 Mar;16(3):208-16. Actas Urol Esp. 1992. PMID: 1621545 Review. Spanish.
-
Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.J Urol. 1993 May;149(5 Pt 2):1288-90. doi: 10.1016/s0022-5347(17)36370-x. J Urol. 1993. PMID: 8479018 Review.
Cited by
-
Medical treatment of impotence with papaverine and phentolamine intracavernosal injection.Ulster Med J. 1990 Oct;59(2):174-6. Ulster Med J. 1990. PMID: 2278115 Free PMC article. Clinical Trial.
-
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.Front Oncol. 2021 Feb 26;11:627229. doi: 10.3389/fonc.2021.627229. eCollection 2021. Front Oncol. 2021. PMID: 33718200 Free PMC article. Review.
-
Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.Acta Diabetol. 1994 Apr;31(1):1-5. doi: 10.1007/BF00580752. Acta Diabetol. 1994. PMID: 8043890
-
Erectile dysfunction.BMJ Clin Evid. 2011 Jun 29;2011:1803. BMJ Clin Evid. 2011. PMID: 21711956 Free PMC article.
-
Diabetic neuropathy part 1: overview and symmetric phenotypes.Neurol Clin. 2013 May;31(2):425-45. doi: 10.1016/j.ncl.2013.02.004. Epub 2013 Mar 15. Neurol Clin. 2013. PMID: 23642717 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical